SCHEMBL30135243

SCHEMBL30135243

CN1CCCNCCCN(Cc2ccon2)CCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 9/20 0.46
MEN1 O00255 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM1 P11229 1/20 0.41
ADRA2C P18825 1/20 0.41
CCR2 P41597 1/20 0.41
CXCL12 P48061 1/20 0.41
BLM P54132 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
CHKA P35790 3/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
CA2 P00918 1/20 0.38
NCF1 P14598 1/20 0.38
PRMT6 Q96LA8 1/20 0.38
LMNA P02545 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1514703 0.82 CXCR4 (0.47) CXCR4MEN1CHRM2CHRM1ADRA2C
SCHEMBL20325711 0.82 MC4R (0.46) MEN1CHRM1KMT2ATDP1CHKA
SCHEMBL18933372 0.78 HRH3 (0.47) MEN1KMT2AHRH3NPC1RAB9A
SCHEMBL30135256 0.72 CXCR4 (0.42) CXCR4MEN1CHRM2CHRM1ADRA2C
SCHEMBL30135254 0.71 CXCR4 (0.75) CXCR4MEN1CHRM2CHRM1ADRA2C
SCHEMBL16044574 0.71 CXCR4 (0.58) CXCR4MEN1KMT2AHRH3NPC1
SCHEMBL22266244 0.70 SIGMAR1 (0.43) CXCR4ALDH1A1
SCHEMBL30135292 0.69 LMNA (0.68) CXCR4MEN1KMT2ACHKALMNA
SCHEMBL22266311 0.68 SIGMAR1 (0.51) CXCR4CHRM2CHRM1HRH3ALDH1A1
SCHEMBL22266323 0.67 SIGMAR1 (0.46) CXCR4CHRM2CHRM1HRH3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600711-B2 Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors KEZAR LIFE SCIENCES, INC. (US) 2026-04-14 US disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G CXCR4 3988/4885MEN1 2214/4885CHRM2 4846/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G CXCR4 3860/4885MEN1 2318/4885CHRM2 4847/4885
US-12600711-B2 Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors CD274, CD40, ICOS CXCR4 1013/4885MEN1 3088/4885CHRM2 3758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.